Hua MedicineHUMDF 46 Days Payable is 103.11 as of Dec. 2025, which is 59% below its 10-year median of 251.03. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 920 Drug Manufacturers companies, Hua Medicine ranks better than 60.87% on this metric.
The historical rank and industry rank for Hua Medicine's Days Payable or its related term are showing as below:
HUMDF'
s Days Payable Range Over the Past 10 Years
Min: 109.07 Med: 251.03 Max: 866.66
Current: 109.07
During the past 10 years, Hua Medicine's highest Days Payable was 866.66. The lowest was 109.07. And the median was 251.03.
HUMDF's Days Payable is ranked better than 60.87% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs HUMDF: 109.07
Hua Medicine's Days Payable
declined
from Dec. 2024 (184.02) to Dec. 2025 (103.11).
It may suggest that Hua Medicineaccelerated paying its suppliers.
Hua Medicine Days Payable Related Terms
Hua Medicine Days Payable Historical Data
* Premium members only.
The historical data trend for Hua Medicine's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Days Payable distribution charts can be found below:
* The bar in red indicates where Hua Medicine's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hua Medicine's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a Days Payable of 103.11 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hua Medicine and its competitors. This is 59% below median its historical median of 251.03. Over the past decade, Hua Medicine's Days Payable has ranged from 109.07 to 866.66. According to the industry distribution chart, Hua Medicine ranks #360 out of 920 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Hua Medicine's Days Payable too high?
Hua Medicine's current Days Payable of 103.11 is 59% below median its 10-year median of 251.03. Over the past 10 years, this metric has ranged from a low of 109.07 to a high of 866.66. The Drug Manufacturers industry median Days Payable is 90.84. Hua Medicine's value of 103.11 is 13.5% above this industry median. Based on the distribution chart, Hua Medicine ranks #360 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #360 out of 920 companies for Days Payable. This puts Hua Medicine in the upper half of its industry. The industry median Days Payable is 90.84. Hua Medicine's value of 103.11 is 13.5% above this benchmark. Historically, Hua Medicine's own Days Payable has ranged from 109.07 to 866.66 over the past decade. While the company's 10-year median is 251.03 vs. the industry median of 90.84, Hua Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current Days Payable of 103.11 is 13.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current Days Payable is 103.11, which is 59% below median its own 10-year median of 251.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current Days Payable is 103.11, which is 59% below median its 10-year median of 251.03 and 13.5% above the Drug Manufacturers industry median of 90.84. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current Days Payable is 103.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
Days Payable: 103.11 (59% below median its 10-year median of 251.03)
GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
Industry Position: 13.5% above the Drug Manufacturers median (#360 of 920)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HUMDF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
